AI Portfolio Summary
In 2026 Q1, CAXTON CORP maintained a portfolio of 12 distinct positions. The most significant new addition to the portfolio was ALX ONCOLOGY HLDGS I, which now represents 1.04% of the total fund value. They heavily accumulated shares in SPDR GOLD TR, increasing their position by 9.5%. Conversely, CAXTON CORP completely exited their position in CONTEXT THERAPEUTICS.
Total Positions
12
Quarter
2026 Q1
Top Holding
GLD (81.5%)
Top 10 Concentration
100.0%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-12 of 12
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
GLD
SPDR GOLD TR
|
ETF | 81.50% | 64.50% |
#1
Prev: #1
|
8.0 | 659 | 9.5% |
P
S
|
7,623 | $3,279,923 |
$195.71
+119.4%
|
2012 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | ||
|
BRK/B
BERKSHIRE HATHA...
|
Financial Services | 8.66% | 8.34% |
#2
Prev: #2
|
5.5 | 17 | 2.4% |
P
S
|
727 | $348,341 |
$153.17
+211.7%
|
2012 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | ||
|
KYTX
KYVERNA THERAPE...
|
Healthcare | 4.03% | 4.12% |
#3
2
Prev: #5
|
3.6 | no change | no change |
P
S
|
18,773 | $162,012 |
$7.50
+18.3%
|
2012 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | ||
|
LXEO
LEXEO THERAPEUT...
|
Healthcare | 1.99% | 3.24% |
#4
3
Prev: #7
|
2.3 | no change | no change |
P
S
|
13,943 | $80,032 | 2012 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
XFOR
X4 PHARMACEUTIC...
|
Healthcare | 1.60% | 1.45% |
#5
3
Prev: #8
|
2.1 | no change | no change |
P
S
|
15,557 | $64,249 | 2012 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
IKT
INHIBIKASE THER...
|
Healthcare | 1.19% | 1.36% |
#6
3
Prev: #9
|
1.5 | no change | no change |
P
S
|
28,453 | $47,801 | 2012 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
ALXO
ALX ONCOLOGY HL...
|
Healthcare | 1.04% | — |
#7
Prev: #—
|
3.9 | 20,946 | no change |
NEW
|
20,946 | $41,996 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
CNTX
CONTEXT THERAPE...
|
Healthcare | 0.00% | 0.63% |
Sold All 😨
(Was: #11) |
0.0 | -18,403 | -100.0% |
CLOSED
|
— | $— | 2012 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
SABS
SAB BIOTHERAPEU...
|
Healthcare | 0.00% | 0.92% |
Sold All 😨
(Was: #10) |
0.0 | -10,527 | -100.0% |
CLOSED
|
— | $— | 2012 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
CMPX
COMPASS THERAPE...
|
Healthcare | 0.00% | 3.70% |
Sold All 😨
(Was: #6) |
0.0 | -29,495 | -100.0% |
CLOSED
|
— | $— | 2012 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
MNMD
MIND MEDICINE M...
|
Unknown | 0.00% | 4.91% |
Sold All 😨
(Was: #4) |
0.0 | -15,688 | -100.0% |
CLOSED
|
— | $— | 2012 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
SYRE
SPYRE THERAPEUT...
|
Healthcare | 0.00% | 6.83% |
Sold All 😨
(Was: #3) |
0.0 | -8,919 | -100.0% |
CLOSED
|
— | $— | 2012 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 |
Showing 1-12 of 12 holdings